Minimal Residual Disease MRD Monitoring for BCLL Test
Introduction
The Minimal Residual Disease MRD Monitoring for BCLL Test is a vital diagnostic tool used in the management of B-cell Chronic Lymphocytic Leukemia (BCLL). This test plays an essential role in assessing the effectiveness of treatment and determining the presence of residual leukemia cells that could lead to relapse. By providing detailed insights into the patient’s disease status, this test helps healthcare providers make informed decisions regarding ongoing therapy.
What the Test Measures
This test detects minimal residual disease, which refers to the small number of leukemia cells that may remain in the body after treatment. The presence of these cells can indicate the likelihood of disease recurrence, making MRD monitoring a critical component of leukemia management.
Who Should Consider This Test
Patients diagnosed with B-cell Chronic Lymphocytic Leukemia (BCLL) should consider this test, especially those undergoing treatment or in remission. Key symptoms and risk factors include:
- Persistent fatigue
- Unexplained weight loss
- Frequent infections
- Swollen lymph nodes
Benefits of Taking the Test
- Monitors treatment effectiveness
- Identifies potential relapse early
- Guides further treatment decisions
- Provides peace of mind for patients and families
Understanding Your Results
Results from the MRD test will indicate whether minimal residual disease is present. A negative result signifies no detectable leukemia cells, while a positive result indicates the presence of residual disease, which may require further intervention.
Test Name and Price
| Test Name | Discount Price | Regular Price |
|---|---|---|
| Minimal Residual Disease MRD Monitoring for BCLL Test | 340,000 NGN | 500,000 NGN |
Booking the Test
To book the Minimal Residual Disease MRD Monitoring for BCLL Test, please contact us at +2348110567037. Our team is ready to assist you with scheduling your appointment and answering any questions you may have.
Test Details
Turnaround Time: Sample Daily by 11 am; Report in 3 Working Days
Sample Type: 3 mL (1 mL min.) Bone Marrow (first pull aspirate) in 1 Green Top (Sodium Heparin) tube AND 4 mL (3 mL min.) whole blood in 2 Green Top (Sodium Heparin) tubes. Mix thoroughly & Ship immediately at 18°C – 22°C or 2-8°C. DO NOT FREEZE.
Pre-test Instructions: Following information is mandatory: Sample time point (Chemotherapy time points); Previous diagnostic immunophenotype report; Clinical history and original TRF; Date and time when sample was drawn to be mentioned on the TRF; Therapy details.
Specialty: Hematology, Oncology
Department: Flow Cytometry
Method: Flow Cytometry
Disease Type: Leukemia
